Theranostics Health Signs Research Collaboration Agreement
News May 16, 2008
This relationship will provide Duke Investigators access to the company's core technologies: Laser Capture Microdissection (LCM) and Reverse Phase Protein Microarray (RPMA).
The proprietary combination of these technologies provides a powerful mechanism to measure the aberrant protein signaling and protein molecular networks used by tumor cells obtained directly from a patient's biopsy. This information can be used to investigate patient-specific treatments and individual treatment regimens, and also, to understand the mechanisms of tumorigenesis in order to discover and develop new, safer and more effective therapies.
According to Dr. Neil Spector, Director of Duke's Translational Research Oncology Program, "those of us at Duke who are going to participate in this umbrella agreement with Theranostics Health are excited about the insight this collaboration may provide on the use of phosphoproteomics to shed light on the complexities of the signaling networks that regulate tumor cell growth, survival, migration/invasion, and resistance to targeted therapies. We are intrigued by the possibility of applying this information to investigate more effective therapies for our patients."
Dr. Danong Chen, President and CEO of Theranostics Health, is equally optimistic about the master research agreement with Duke. "We are very pleased to begin collaboration with a nationally-recognized center of excellence and believe that Duke shares our vision of shaping a new paradigm in disease management. This relationship demonstrates the value of this technology for impacting healthcare delivery."